No Data
SA Asks: Which Biotechs Are Most Likely to Be Acquired Near-term?
AstraZeneca PLC Stock Flat Friday
AstraZeneca (AZN.US) has initiated a Phase III clinical trial for the PD-1/TIGIT dual antibody.
AstraZeneca (AZN.US) has launched Phase III clinical trials for its PD-1/TIGIT dual antibody.
AstraZeneca Call Volume Above Normal and Directionally Bullish
Unusual Options Activity: NCLH, AZN and Others Attract Market Bets, NCLH V/OI Ratio Reaches 55.6
AstraZeneca Announces Share Capital and Voting Rights Update
loading...
NoobGirl : bro is this real that roaring kitty gonna come?